Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Director/PDMR Shareholding

27 Jun 2008 15:47

Immediate Release: Friday 27th June 2008

SOPHEON PLC DIRECTORS' SHAREHOLDINGS

Sopheon plc ("Sopheon") announces that it has granted options over Sopheon Ordinary Shares to certain directors as part of a grant of options to certain members of management and staff of the group. The options have been granted at a price of 14.00p per share, being the closing price on 26 June 2008. As part of this grant, Andrew Michuda and Arif Karimjee, being respectively Sopheon's CEO and CFO, have been granted options over 230,000 and 100,000 ordinary shares respectively.

In conjunction with the above grant, certain options previously granted to UK employees have been cancelled and re-issued under a more tax efficient structure. This action includes options that had been granted to Arif Karimjee, comprising options over 200,000 shares at 16.25p granted on 5 November 2003, and options over 100,000 shares at 19.00p granted on 29 June 2007. Apart from the tax basis under which they were granted, all conditions with respect to these options are unchanged from their original basis. Accordingly, the new options have been granted at the original prices of 16.25p and 19.00p respectively.

For further information contact:

Barry Mence, Chairman Sopheon plc + 44 (0) 1483 685 735 Arif Karimjee, CFO Vikki Krause Hansard + 44 (0) 207 245 1100 Communications + 44 (0) 7957 203 685 Claire Verhagen Citigate First + 31 (0) 205 754 010 Financial

Paul Davies, Corporate Finance Seymour Pierce + 44 (0) 207 107 8000 Richard Redmayne, Corpoate

Broking

vendor
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.